Dynamic Contrast-enhanced and Diffusion-weighted Magnetic Resonance Imaging for Response Evaluation After Single-Dose Ablative Neoadjuvant Partial Breast Irradiation

Purpose: We aimed to evaluate changes in dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) scans acquired before and after single-dose ablative neoadjuvant partial breast irradiation (NA-PBI), and explore the relation between semiquantitative MRI parameters and radiologic and pathologic responses. Methods and Materials: We analyzed 3.0T DCE and DW-MRI of 36 patients with low-risk breast cancer who were treated with single-dose NA-PBI, followed by breast-conserving surgery 6 or 8 months later. MRI was acquired before NA-PBI and 1 week, 2, 4, and 6 months after NA-PBI. Breast radiologists assessed the radiologic response and breast pathologists scored the pathologic response after surgery. Patients were grouped as either pathologic responders or nonresponders (<10% vs ≥10% residual tumor cells). The semiquantitative MRI parameters evaluated were time to enhancement (TTE), 1-minute relative enhancement (RE1min), percentage of enhancing voxels (%EV), distribution of washout curve types, and apparent diffusion coefficient (ADC). Results: In general, the enhancement increased 1 week after NA-PBI (baseline vs 1 week median – TTE: 15s vs 10s; RE1min: 161% vs 197%; %EV: 47% vs 67%) and decreased from 2 months onward (6 months median – TTE: 25s; RE1min: 86%; %EV: 12%). Median ADC increased from 0.83 × 10−3 mm2/s at baseline to 1.28 × 10−3 mm2/s at 6 months. TTE, RE1min, and %EV showed the most potential to differentiate between radiologic responses, and TTE, RE1min, and ADC between pathologic responses. Conclusions: Semiquantitative analyses of DCE and DW-MRI showed changes in relative enhancement and ADC 1 week after NA-PBI, indicating acute inflammation, followed by changes indicating tumor regression from 2 to 6 months after radiation therapy. A relation between the MRI parameters and radiologic and pathologic responses could not be proven in this exploratory study. Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Jeanine E. Vasmel, MD [verfasserIn] Maureen L. Groot Koerkamp, MSc [verfasserIn] Stefano Mandija, PhD [verfasserIn] Wouter B. Veldhuis, PhD [verfasserIn] Maaike R. Moman, PhD [verfasserIn] Martijn Froeling, PhD [verfasserIn] Bas H.M. van der Velden, PhD [verfasserIn] Ramona K. Charaghvandi, PhD [verfasserIn] Celien P.H. Vreuls, PhD [verfasserIn] Paul J. van Diest, PhD [verfasserIn] A.M. Gijs van Leeuwen, MD [verfasserIn] Joost van Gorp, PhD [verfasserIn] Marielle E.P. Philippens, PhD [verfasserIn] Bram van Asselen, PhD [verfasserIn] Jan J.W. Lagendijk, PhD [verfasserIn] Helena M. Verkooijen, PhD [verfasserIn] H.J.G. Desirée van den Bongard, PhD [verfasserIn] Antonetta C. Houweling, PhD [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2022

Übergeordnetes Werk:	In: Advances in Radiation Oncology - Elsevier, 2016, 7(2022), 2, Seite 100854-
Übergeordnetes Werk:	volume:7 ; year:2022 ; number:2 ; pages:100854-

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1016/j.adro.2021.100854

Katalog-ID:	DOAJ075338785

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ075338785
003	DE-627
005	20230309133523.0
007	cr uuu---uuuuu
008	230228s2022 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.adro.2021.100854 \|2 doi
035			\|a (DE-627)DOAJ075338785
035			\|a (DE-599)DOAJ751cb4f60910424aab7700d239593d68
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a R895-920
050		0	\|a RC254-282
100	0		\|a Jeanine E. Vasmel, MD \|e verfasserin \|4 aut
245	1	0	\|a Dynamic Contrast-enhanced and Diffusion-weighted Magnetic Resonance Imaging for Response Evaluation After Single-Dose Ablative Neoadjuvant Partial Breast Irradiation
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Purpose: We aimed to evaluate changes in dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) scans acquired before and after single-dose ablative neoadjuvant partial breast irradiation (NA-PBI), and explore the relation between semiquantitative MRI parameters and radiologic and pathologic responses. Methods and Materials: We analyzed 3.0T DCE and DW-MRI of 36 patients with low-risk breast cancer who were treated with single-dose NA-PBI, followed by breast-conserving surgery 6 or 8 months later. MRI was acquired before NA-PBI and 1 week, 2, 4, and 6 months after NA-PBI. Breast radiologists assessed the radiologic response and breast pathologists scored the pathologic response after surgery. Patients were grouped as either pathologic responders or nonresponders (<10% vs ≥10% residual tumor cells). The semiquantitative MRI parameters evaluated were time to enhancement (TTE), 1-minute relative enhancement (RE1min), percentage of enhancing voxels (%EV), distribution of washout curve types, and apparent diffusion coefficient (ADC). Results: In general, the enhancement increased 1 week after NA-PBI (baseline vs 1 week median – TTE: 15s vs 10s; RE1min: 161% vs 197%; %EV: 47% vs 67%) and decreased from 2 months onward (6 months median – TTE: 25s; RE1min: 86%; %EV: 12%). Median ADC increased from 0.83 × 10−3 mm2/s at baseline to 1.28 × 10−3 mm2/s at 6 months. TTE, RE1min, and %EV showed the most potential to differentiate between radiologic responses, and TTE, RE1min, and ADC between pathologic responses. Conclusions: Semiquantitative analyses of DCE and DW-MRI showed changes in relative enhancement and ADC 1 week after NA-PBI, indicating acute inflammation, followed by changes indicating tumor regression from 2 to 6 months after radiation therapy. A relation between the MRI parameters and radiologic and pathologic responses could not be proven in this exploratory study.
653		0	\|a Medical physics. Medical radiology. Nuclear medicine
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a Maureen L. Groot Koerkamp, MSc \|e verfasserin \|4 aut
700	0		\|a Stefano Mandija, PhD \|e verfasserin \|4 aut
700	0		\|a Wouter B. Veldhuis, PhD \|e verfasserin \|4 aut
700	0		\|a Maaike R. Moman, PhD \|e verfasserin \|4 aut
700	0		\|a Martijn Froeling, PhD \|e verfasserin \|4 aut
700	0		\|a Bas H.M. van der Velden, PhD \|e verfasserin \|4 aut
700	0		\|a Ramona K. Charaghvandi, PhD \|e verfasserin \|4 aut
700	0		\|a Celien P.H. Vreuls, PhD \|e verfasserin \|4 aut
700	0		\|a Paul J. van Diest, PhD \|e verfasserin \|4 aut
700	0		\|a A.M. Gijs van Leeuwen, MD \|e verfasserin \|4 aut
700	0		\|a Joost van Gorp, PhD \|e verfasserin \|4 aut
700	0		\|a Marielle E.P. Philippens, PhD \|e verfasserin \|4 aut
700	0		\|a Bram van Asselen, PhD \|e verfasserin \|4 aut
700	0		\|a Jan J.W. Lagendijk, PhD \|e verfasserin \|4 aut
700	0		\|a Helena M. Verkooijen, PhD \|e verfasserin \|4 aut
700	0		\|a H.J.G. Desirée van den Bongard, PhD \|e verfasserin \|4 aut
700	0		\|a Antonetta C. Houweling, PhD \|e verfasserin \|4 aut
773	0	8	\|i In \|t Advances in Radiation Oncology \|d Elsevier, 2016 \|g 7(2022), 2, Seite 100854- \|w (DE-627)848324579 \|w (DE-600)2847724-8 \|x 24521094 \|7 nnns
773	1	8	\|g volume:7 \|g year:2022 \|g number:2 \|g pages:100854-
856	4	0	\|u https://doi.org/10.1016/j.adro.2021.100854 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/751cb4f60910424aab7700d239593d68 \|z kostenfrei
856	4	0	\|u http://www.sciencedirect.com/science/article/pii/S2452109421002128 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2452-1094 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 7 \|j 2022 \|e 2 \|h 100854-

Indexfelder

author_variant	e v m j evm evmj l g k m m lgkm lgkmm m p s mp mps b v p w bvp bvpw r m p m rmp rmpm f p m fp fpm h v d v p b hvdvp hvdvpb k c p r kcp kcpr p v p c pvp pvpc j v d p p jvdp jvdpp g v l m a gvlm gvlma v g p j vgp vgpj e p p m epp eppm v a p b vap vapb j l p j jlp jlpj m v p h mvp mvph d v d b p h dvdbp dvdbph c h p a chp chpa
matchkey_str	article:24521094:2022----::yaicnrsehneadifsowihemgeirsnnemgnfrepnevlainfesnldsalt
hierarchy_sort_str	2022
callnumber-subject-code	R
publishDate	2022
allfields	10.1016/j.adro.2021.100854 doi (DE-627)DOAJ075338785 (DE-599)DOAJ751cb4f60910424aab7700d239593d68 DE-627 ger DE-627 rakwb eng R895-920 RC254-282 Jeanine E. Vasmel, MD verfasserin aut Dynamic Contrast-enhanced and Diffusion-weighted Magnetic Resonance Imaging for Response Evaluation After Single-Dose Ablative Neoadjuvant Partial Breast Irradiation 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose: We aimed to evaluate changes in dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) scans acquired before and after single-dose ablative neoadjuvant partial breast irradiation (NA-PBI), and explore the relation between semiquantitative MRI parameters and radiologic and pathologic responses. Methods and Materials: We analyzed 3.0T DCE and DW-MRI of 36 patients with low-risk breast cancer who were treated with single-dose NA-PBI, followed by breast-conserving surgery 6 or 8 months later. MRI was acquired before NA-PBI and 1 week, 2, 4, and 6 months after NA-PBI. Breast radiologists assessed the radiologic response and breast pathologists scored the pathologic response after surgery. Patients were grouped as either pathologic responders or nonresponders (<10% vs ≥10% residual tumor cells). The semiquantitative MRI parameters evaluated were time to enhancement (TTE), 1-minute relative enhancement (RE1min), percentage of enhancing voxels (%EV), distribution of washout curve types, and apparent diffusion coefficient (ADC). Results: In general, the enhancement increased 1 week after NA-PBI (baseline vs 1 week median – TTE: 15s vs 10s; RE1min: 161% vs 197%; %EV: 47% vs 67%) and decreased from 2 months onward (6 months median – TTE: 25s; RE1min: 86%; %EV: 12%). Median ADC increased from 0.83 × 10−3 mm2/s at baseline to 1.28 × 10−3 mm2/s at 6 months. TTE, RE1min, and %EV showed the most potential to differentiate between radiologic responses, and TTE, RE1min, and ADC between pathologic responses. Conclusions: Semiquantitative analyses of DCE and DW-MRI showed changes in relative enhancement and ADC 1 week after NA-PBI, indicating acute inflammation, followed by changes indicating tumor regression from 2 to 6 months after radiation therapy. A relation between the MRI parameters and radiologic and pathologic responses could not be proven in this exploratory study. Medical physics. Medical radiology. Nuclear medicine Neoplasms. Tumors. Oncology. Including cancer and carcinogens Maureen L. Groot Koerkamp, MSc verfasserin aut Stefano Mandija, PhD verfasserin aut Wouter B. Veldhuis, PhD verfasserin aut Maaike R. Moman, PhD verfasserin aut Martijn Froeling, PhD verfasserin aut Bas H.M. van der Velden, PhD verfasserin aut Ramona K. Charaghvandi, PhD verfasserin aut Celien P.H. Vreuls, PhD verfasserin aut Paul J. van Diest, PhD verfasserin aut A.M. Gijs van Leeuwen, MD verfasserin aut Joost van Gorp, PhD verfasserin aut Marielle E.P. Philippens, PhD verfasserin aut Bram van Asselen, PhD verfasserin aut Jan J.W. Lagendijk, PhD verfasserin aut Helena M. Verkooijen, PhD verfasserin aut H.J.G. Desirée van den Bongard, PhD verfasserin aut Antonetta C. Houweling, PhD verfasserin aut In Advances in Radiation Oncology Elsevier, 2016 7(2022), 2, Seite 100854- (DE-627)848324579 (DE-600)2847724-8 24521094 nnns volume:7 year:2022 number:2 pages:100854- https://doi.org/10.1016/j.adro.2021.100854 kostenfrei https://doaj.org/article/751cb4f60910424aab7700d239593d68 kostenfrei http://www.sciencedirect.com/science/article/pii/S2452109421002128 kostenfrei https://doaj.org/toc/2452-1094 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2022 2 100854-
spelling	10.1016/j.adro.2021.100854 doi (DE-627)DOAJ075338785 (DE-599)DOAJ751cb4f60910424aab7700d239593d68 DE-627 ger DE-627 rakwb eng R895-920 RC254-282 Jeanine E. Vasmel, MD verfasserin aut Dynamic Contrast-enhanced and Diffusion-weighted Magnetic Resonance Imaging for Response Evaluation After Single-Dose Ablative Neoadjuvant Partial Breast Irradiation 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose: We aimed to evaluate changes in dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) scans acquired before and after single-dose ablative neoadjuvant partial breast irradiation (NA-PBI), and explore the relation between semiquantitative MRI parameters and radiologic and pathologic responses. Methods and Materials: We analyzed 3.0T DCE and DW-MRI of 36 patients with low-risk breast cancer who were treated with single-dose NA-PBI, followed by breast-conserving surgery 6 or 8 months later. MRI was acquired before NA-PBI and 1 week, 2, 4, and 6 months after NA-PBI. Breast radiologists assessed the radiologic response and breast pathologists scored the pathologic response after surgery. Patients were grouped as either pathologic responders or nonresponders (<10% vs ≥10% residual tumor cells). The semiquantitative MRI parameters evaluated were time to enhancement (TTE), 1-minute relative enhancement (RE1min), percentage of enhancing voxels (%EV), distribution of washout curve types, and apparent diffusion coefficient (ADC). Results: In general, the enhancement increased 1 week after NA-PBI (baseline vs 1 week median – TTE: 15s vs 10s; RE1min: 161% vs 197%; %EV: 47% vs 67%) and decreased from 2 months onward (6 months median – TTE: 25s; RE1min: 86%; %EV: 12%). Median ADC increased from 0.83 × 10−3 mm2/s at baseline to 1.28 × 10−3 mm2/s at 6 months. TTE, RE1min, and %EV showed the most potential to differentiate between radiologic responses, and TTE, RE1min, and ADC between pathologic responses. Conclusions: Semiquantitative analyses of DCE and DW-MRI showed changes in relative enhancement and ADC 1 week after NA-PBI, indicating acute inflammation, followed by changes indicating tumor regression from 2 to 6 months after radiation therapy. A relation between the MRI parameters and radiologic and pathologic responses could not be proven in this exploratory study. Medical physics. Medical radiology. Nuclear medicine Neoplasms. Tumors. Oncology. Including cancer and carcinogens Maureen L. Groot Koerkamp, MSc verfasserin aut Stefano Mandija, PhD verfasserin aut Wouter B. Veldhuis, PhD verfasserin aut Maaike R. Moman, PhD verfasserin aut Martijn Froeling, PhD verfasserin aut Bas H.M. van der Velden, PhD verfasserin aut Ramona K. Charaghvandi, PhD verfasserin aut Celien P.H. Vreuls, PhD verfasserin aut Paul J. van Diest, PhD verfasserin aut A.M. Gijs van Leeuwen, MD verfasserin aut Joost van Gorp, PhD verfasserin aut Marielle E.P. Philippens, PhD verfasserin aut Bram van Asselen, PhD verfasserin aut Jan J.W. Lagendijk, PhD verfasserin aut Helena M. Verkooijen, PhD verfasserin aut H.J.G. Desirée van den Bongard, PhD verfasserin aut Antonetta C. Houweling, PhD verfasserin aut In Advances in Radiation Oncology Elsevier, 2016 7(2022), 2, Seite 100854- (DE-627)848324579 (DE-600)2847724-8 24521094 nnns volume:7 year:2022 number:2 pages:100854- https://doi.org/10.1016/j.adro.2021.100854 kostenfrei https://doaj.org/article/751cb4f60910424aab7700d239593d68 kostenfrei http://www.sciencedirect.com/science/article/pii/S2452109421002128 kostenfrei https://doaj.org/toc/2452-1094 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2022 2 100854-
allfields_unstemmed	10.1016/j.adro.2021.100854 doi (DE-627)DOAJ075338785 (DE-599)DOAJ751cb4f60910424aab7700d239593d68 DE-627 ger DE-627 rakwb eng R895-920 RC254-282 Jeanine E. Vasmel, MD verfasserin aut Dynamic Contrast-enhanced and Diffusion-weighted Magnetic Resonance Imaging for Response Evaluation After Single-Dose Ablative Neoadjuvant Partial Breast Irradiation 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose: We aimed to evaluate changes in dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) scans acquired before and after single-dose ablative neoadjuvant partial breast irradiation (NA-PBI), and explore the relation between semiquantitative MRI parameters and radiologic and pathologic responses. Methods and Materials: We analyzed 3.0T DCE and DW-MRI of 36 patients with low-risk breast cancer who were treated with single-dose NA-PBI, followed by breast-conserving surgery 6 or 8 months later. MRI was acquired before NA-PBI and 1 week, 2, 4, and 6 months after NA-PBI. Breast radiologists assessed the radiologic response and breast pathologists scored the pathologic response after surgery. Patients were grouped as either pathologic responders or nonresponders (<10% vs ≥10% residual tumor cells). The semiquantitative MRI parameters evaluated were time to enhancement (TTE), 1-minute relative enhancement (RE1min), percentage of enhancing voxels (%EV), distribution of washout curve types, and apparent diffusion coefficient (ADC). Results: In general, the enhancement increased 1 week after NA-PBI (baseline vs 1 week median – TTE: 15s vs 10s; RE1min: 161% vs 197%; %EV: 47% vs 67%) and decreased from 2 months onward (6 months median – TTE: 25s; RE1min: 86%; %EV: 12%). Median ADC increased from 0.83 × 10−3 mm2/s at baseline to 1.28 × 10−3 mm2/s at 6 months. TTE, RE1min, and %EV showed the most potential to differentiate between radiologic responses, and TTE, RE1min, and ADC between pathologic responses. Conclusions: Semiquantitative analyses of DCE and DW-MRI showed changes in relative enhancement and ADC 1 week after NA-PBI, indicating acute inflammation, followed by changes indicating tumor regression from 2 to 6 months after radiation therapy. A relation between the MRI parameters and radiologic and pathologic responses could not be proven in this exploratory study. Medical physics. Medical radiology. Nuclear medicine Neoplasms. Tumors. Oncology. Including cancer and carcinogens Maureen L. Groot Koerkamp, MSc verfasserin aut Stefano Mandija, PhD verfasserin aut Wouter B. Veldhuis, PhD verfasserin aut Maaike R. Moman, PhD verfasserin aut Martijn Froeling, PhD verfasserin aut Bas H.M. van der Velden, PhD verfasserin aut Ramona K. Charaghvandi, PhD verfasserin aut Celien P.H. Vreuls, PhD verfasserin aut Paul J. van Diest, PhD verfasserin aut A.M. Gijs van Leeuwen, MD verfasserin aut Joost van Gorp, PhD verfasserin aut Marielle E.P. Philippens, PhD verfasserin aut Bram van Asselen, PhD verfasserin aut Jan J.W. Lagendijk, PhD verfasserin aut Helena M. Verkooijen, PhD verfasserin aut H.J.G. Desirée van den Bongard, PhD verfasserin aut Antonetta C. Houweling, PhD verfasserin aut In Advances in Radiation Oncology Elsevier, 2016 7(2022), 2, Seite 100854- (DE-627)848324579 (DE-600)2847724-8 24521094 nnns volume:7 year:2022 number:2 pages:100854- https://doi.org/10.1016/j.adro.2021.100854 kostenfrei https://doaj.org/article/751cb4f60910424aab7700d239593d68 kostenfrei http://www.sciencedirect.com/science/article/pii/S2452109421002128 kostenfrei https://doaj.org/toc/2452-1094 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2022 2 100854-
allfieldsGer	10.1016/j.adro.2021.100854 doi (DE-627)DOAJ075338785 (DE-599)DOAJ751cb4f60910424aab7700d239593d68 DE-627 ger DE-627 rakwb eng R895-920 RC254-282 Jeanine E. Vasmel, MD verfasserin aut Dynamic Contrast-enhanced and Diffusion-weighted Magnetic Resonance Imaging for Response Evaluation After Single-Dose Ablative Neoadjuvant Partial Breast Irradiation 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose: We aimed to evaluate changes in dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) scans acquired before and after single-dose ablative neoadjuvant partial breast irradiation (NA-PBI), and explore the relation between semiquantitative MRI parameters and radiologic and pathologic responses. Methods and Materials: We analyzed 3.0T DCE and DW-MRI of 36 patients with low-risk breast cancer who were treated with single-dose NA-PBI, followed by breast-conserving surgery 6 or 8 months later. MRI was acquired before NA-PBI and 1 week, 2, 4, and 6 months after NA-PBI. Breast radiologists assessed the radiologic response and breast pathologists scored the pathologic response after surgery. Patients were grouped as either pathologic responders or nonresponders (<10% vs ≥10% residual tumor cells). The semiquantitative MRI parameters evaluated were time to enhancement (TTE), 1-minute relative enhancement (RE1min), percentage of enhancing voxels (%EV), distribution of washout curve types, and apparent diffusion coefficient (ADC). Results: In general, the enhancement increased 1 week after NA-PBI (baseline vs 1 week median – TTE: 15s vs 10s; RE1min: 161% vs 197%; %EV: 47% vs 67%) and decreased from 2 months onward (6 months median – TTE: 25s; RE1min: 86%; %EV: 12%). Median ADC increased from 0.83 × 10−3 mm2/s at baseline to 1.28 × 10−3 mm2/s at 6 months. TTE, RE1min, and %EV showed the most potential to differentiate between radiologic responses, and TTE, RE1min, and ADC between pathologic responses. Conclusions: Semiquantitative analyses of DCE and DW-MRI showed changes in relative enhancement and ADC 1 week after NA-PBI, indicating acute inflammation, followed by changes indicating tumor regression from 2 to 6 months after radiation therapy. A relation between the MRI parameters and radiologic and pathologic responses could not be proven in this exploratory study. Medical physics. Medical radiology. Nuclear medicine Neoplasms. Tumors. Oncology. Including cancer and carcinogens Maureen L. Groot Koerkamp, MSc verfasserin aut Stefano Mandija, PhD verfasserin aut Wouter B. Veldhuis, PhD verfasserin aut Maaike R. Moman, PhD verfasserin aut Martijn Froeling, PhD verfasserin aut Bas H.M. van der Velden, PhD verfasserin aut Ramona K. Charaghvandi, PhD verfasserin aut Celien P.H. Vreuls, PhD verfasserin aut Paul J. van Diest, PhD verfasserin aut A.M. Gijs van Leeuwen, MD verfasserin aut Joost van Gorp, PhD verfasserin aut Marielle E.P. Philippens, PhD verfasserin aut Bram van Asselen, PhD verfasserin aut Jan J.W. Lagendijk, PhD verfasserin aut Helena M. Verkooijen, PhD verfasserin aut H.J.G. Desirée van den Bongard, PhD verfasserin aut Antonetta C. Houweling, PhD verfasserin aut In Advances in Radiation Oncology Elsevier, 2016 7(2022), 2, Seite 100854- (DE-627)848324579 (DE-600)2847724-8 24521094 nnns volume:7 year:2022 number:2 pages:100854- https://doi.org/10.1016/j.adro.2021.100854 kostenfrei https://doaj.org/article/751cb4f60910424aab7700d239593d68 kostenfrei http://www.sciencedirect.com/science/article/pii/S2452109421002128 kostenfrei https://doaj.org/toc/2452-1094 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2022 2 100854-
allfieldsSound	10.1016/j.adro.2021.100854 doi (DE-627)DOAJ075338785 (DE-599)DOAJ751cb4f60910424aab7700d239593d68 DE-627 ger DE-627 rakwb eng R895-920 RC254-282 Jeanine E. Vasmel, MD verfasserin aut Dynamic Contrast-enhanced and Diffusion-weighted Magnetic Resonance Imaging for Response Evaluation After Single-Dose Ablative Neoadjuvant Partial Breast Irradiation 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Purpose: We aimed to evaluate changes in dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) scans acquired before and after single-dose ablative neoadjuvant partial breast irradiation (NA-PBI), and explore the relation between semiquantitative MRI parameters and radiologic and pathologic responses. Methods and Materials: We analyzed 3.0T DCE and DW-MRI of 36 patients with low-risk breast cancer who were treated with single-dose NA-PBI, followed by breast-conserving surgery 6 or 8 months later. MRI was acquired before NA-PBI and 1 week, 2, 4, and 6 months after NA-PBI. Breast radiologists assessed the radiologic response and breast pathologists scored the pathologic response after surgery. Patients were grouped as either pathologic responders or nonresponders (<10% vs ≥10% residual tumor cells). The semiquantitative MRI parameters evaluated were time to enhancement (TTE), 1-minute relative enhancement (RE1min), percentage of enhancing voxels (%EV), distribution of washout curve types, and apparent diffusion coefficient (ADC). Results: In general, the enhancement increased 1 week after NA-PBI (baseline vs 1 week median – TTE: 15s vs 10s; RE1min: 161% vs 197%; %EV: 47% vs 67%) and decreased from 2 months onward (6 months median – TTE: 25s; RE1min: 86%; %EV: 12%). Median ADC increased from 0.83 × 10−3 mm2/s at baseline to 1.28 × 10−3 mm2/s at 6 months. TTE, RE1min, and %EV showed the most potential to differentiate between radiologic responses, and TTE, RE1min, and ADC between pathologic responses. Conclusions: Semiquantitative analyses of DCE and DW-MRI showed changes in relative enhancement and ADC 1 week after NA-PBI, indicating acute inflammation, followed by changes indicating tumor regression from 2 to 6 months after radiation therapy. A relation between the MRI parameters and radiologic and pathologic responses could not be proven in this exploratory study. Medical physics. Medical radiology. Nuclear medicine Neoplasms. Tumors. Oncology. Including cancer and carcinogens Maureen L. Groot Koerkamp, MSc verfasserin aut Stefano Mandija, PhD verfasserin aut Wouter B. Veldhuis, PhD verfasserin aut Maaike R. Moman, PhD verfasserin aut Martijn Froeling, PhD verfasserin aut Bas H.M. van der Velden, PhD verfasserin aut Ramona K. Charaghvandi, PhD verfasserin aut Celien P.H. Vreuls, PhD verfasserin aut Paul J. van Diest, PhD verfasserin aut A.M. Gijs van Leeuwen, MD verfasserin aut Joost van Gorp, PhD verfasserin aut Marielle E.P. Philippens, PhD verfasserin aut Bram van Asselen, PhD verfasserin aut Jan J.W. Lagendijk, PhD verfasserin aut Helena M. Verkooijen, PhD verfasserin aut H.J.G. Desirée van den Bongard, PhD verfasserin aut Antonetta C. Houweling, PhD verfasserin aut In Advances in Radiation Oncology Elsevier, 2016 7(2022), 2, Seite 100854- (DE-627)848324579 (DE-600)2847724-8 24521094 nnns volume:7 year:2022 number:2 pages:100854- https://doi.org/10.1016/j.adro.2021.100854 kostenfrei https://doaj.org/article/751cb4f60910424aab7700d239593d68 kostenfrei http://www.sciencedirect.com/science/article/pii/S2452109421002128 kostenfrei https://doaj.org/toc/2452-1094 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2022 2 100854-
language	English
source	In Advances in Radiation Oncology 7(2022), 2, Seite 100854- volume:7 year:2022 number:2 pages:100854-
sourceStr	In Advances in Radiation Oncology 7(2022), 2, Seite 100854- volume:7 year:2022 number:2 pages:100854-
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Medical physics. Medical radiology. Nuclear medicine Neoplasms. Tumors. Oncology. Including cancer and carcinogens
isfreeaccess_bool	true
container_title	Advances in Radiation Oncology
authorswithroles_txt_mv	Jeanine E. Vasmel, MD @@aut@@ Maureen L. Groot Koerkamp, MSc @@aut@@ Stefano Mandija, PhD @@aut@@ Wouter B. Veldhuis, PhD @@aut@@ Maaike R. Moman, PhD @@aut@@ Martijn Froeling, PhD @@aut@@ Bas H.M. van der Velden, PhD @@aut@@ Ramona K. Charaghvandi, PhD @@aut@@ Celien P.H. Vreuls, PhD @@aut@@ Paul J. van Diest, PhD @@aut@@ A.M. Gijs van Leeuwen, MD @@aut@@ Joost van Gorp, PhD @@aut@@ Marielle E.P. Philippens, PhD @@aut@@ Bram van Asselen, PhD @@aut@@ Jan J.W. Lagendijk, PhD @@aut@@ Helena M. Verkooijen, PhD @@aut@@ H.J.G. Desirée van den Bongard, PhD @@aut@@ Antonetta C. Houweling, PhD @@aut@@
publishDateDaySort_date	2022-01-01T00:00:00Z
hierarchy_top_id	848324579
id	DOAJ075338785
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ075338785</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309133523.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.adro.2021.100854</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ075338785</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ751cb4f60910424aab7700d239593d68</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R895-920</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Jeanine E. Vasmel, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Dynamic Contrast-enhanced and Diffusion-weighted Magnetic Resonance Imaging for Response Evaluation After Single-Dose Ablative Neoadjuvant Partial Breast Irradiation</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose: We aimed to evaluate changes in dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) scans acquired before and after single-dose ablative neoadjuvant partial breast irradiation (NA-PBI), and explore the relation between semiquantitative MRI parameters and radiologic and pathologic responses. Methods and Materials: We analyzed 3.0T DCE and DW-MRI of 36 patients with low-risk breast cancer who were treated with single-dose NA-PBI, followed by breast-conserving surgery 6 or 8 months later. MRI was acquired before NA-PBI and 1 week, 2, 4, and 6 months after NA-PBI. Breast radiologists assessed the radiologic response and breast pathologists scored the pathologic response after surgery. Patients were grouped as either pathologic responders or nonresponders (<10% vs ≥10% residual tumor cells). The semiquantitative MRI parameters evaluated were time to enhancement (TTE), 1-minute relative enhancement (RE1min), percentage of enhancing voxels (%EV), distribution of washout curve types, and apparent diffusion coefficient (ADC). Results: In general, the enhancement increased 1 week after NA-PBI (baseline vs 1 week median – TTE: 15s vs 10s; RE1min: 161% vs 197%; %EV: 47% vs 67%) and decreased from 2 months onward (6 months median – TTE: 25s; RE1min: 86%; %EV: 12%). Median ADC increased from 0.83 × 10−3 mm2/s at baseline to 1.28 × 10−3 mm2/s at 6 months. TTE, RE1min, and %EV showed the most potential to differentiate between radiologic responses, and TTE, RE1min, and ADC between pathologic responses. Conclusions: Semiquantitative analyses of DCE and DW-MRI showed changes in relative enhancement and ADC 1 week after NA-PBI, indicating acute inflammation, followed by changes indicating tumor regression from 2 to 6 months after radiation therapy. A relation between the MRI parameters and radiologic and pathologic responses could not be proven in this exploratory study.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical physics. Medical radiology. Nuclear medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maureen L. Groot Koerkamp, MSc</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stefano Mandija, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Wouter B. Veldhuis, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maaike R. Moman, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Martijn Froeling, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bas H.M. van der Velden, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ramona K. Charaghvandi, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Celien P.H. Vreuls, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paul J. van Diest, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A.M. Gijs van Leeuwen, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Joost van Gorp, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marielle E.P. Philippens, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bram van Asselen, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jan J.W. Lagendijk, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Helena M. Verkooijen, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">H.J.G. Desirée van den Bongard, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonetta C. Houweling, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Advances in Radiation Oncology</subfield><subfield code="d">Elsevier, 2016</subfield><subfield code="g">7(2022), 2, Seite 100854-</subfield><subfield code="w">(DE-627)848324579</subfield><subfield code="w">(DE-600)2847724-8</subfield><subfield code="x">24521094</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:100854-</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.adro.2021.100854</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/751cb4f60910424aab7700d239593d68</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S2452109421002128</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2452-1094</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2022</subfield><subfield code="e">2</subfield><subfield code="h">100854-</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Jeanine E. Vasmel, MD
spellingShingle	Jeanine E. Vasmel, MD misc R895-920 misc RC254-282 misc Medical physics. Medical radiology. Nuclear medicine misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Dynamic Contrast-enhanced and Diffusion-weighted Magnetic Resonance Imaging for Response Evaluation After Single-Dose Ablative Neoadjuvant Partial Breast Irradiation
authorStr	Jeanine E. Vasmel, MD
ppnlink_with_tag_str_mv	@@773@@(DE-627)848324579
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	R895-920
illustrated	Not Illustrated
issn	24521094
topic_title	R895-920 RC254-282 Dynamic Contrast-enhanced and Diffusion-weighted Magnetic Resonance Imaging for Response Evaluation After Single-Dose Ablative Neoadjuvant Partial Breast Irradiation
topic	misc R895-920 misc RC254-282 misc Medical physics. Medical radiology. Nuclear medicine misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_unstemmed	misc R895-920 misc RC254-282 misc Medical physics. Medical radiology. Nuclear medicine misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_browse	misc R895-920 misc RC254-282 misc Medical physics. Medical radiology. Nuclear medicine misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Advances in Radiation Oncology
hierarchy_parent_id	848324579
hierarchy_top_title	Advances in Radiation Oncology
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)848324579 (DE-600)2847724-8
title	Dynamic Contrast-enhanced and Diffusion-weighted Magnetic Resonance Imaging for Response Evaluation After Single-Dose Ablative Neoadjuvant Partial Breast Irradiation
ctrlnum	(DE-627)DOAJ075338785 (DE-599)DOAJ751cb4f60910424aab7700d239593d68
title_full	Dynamic Contrast-enhanced and Diffusion-weighted Magnetic Resonance Imaging for Response Evaluation After Single-Dose Ablative Neoadjuvant Partial Breast Irradiation
author_sort	Jeanine E. Vasmel, MD
journal	Advances in Radiation Oncology
journalStr	Advances in Radiation Oncology
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2022
contenttype_str_mv	txt
container_start_page	100854
author_browse	Jeanine E. Vasmel, MD Maureen L. Groot Koerkamp, MSc Stefano Mandija, PhD Wouter B. Veldhuis, PhD Maaike R. Moman, PhD Martijn Froeling, PhD Bas H.M. van der Velden, PhD Ramona K. Charaghvandi, PhD Celien P.H. Vreuls, PhD Paul J. van Diest, PhD A.M. Gijs van Leeuwen, MD Joost van Gorp, PhD Marielle E.P. Philippens, PhD Bram van Asselen, PhD Jan J.W. Lagendijk, PhD Helena M. Verkooijen, PhD H.J.G. Desirée van den Bongard, PhD Antonetta C. Houweling, PhD
container_volume	7
class	R895-920 RC254-282
format_se	Elektronische Aufsätze
author-letter	Jeanine E. Vasmel, MD
doi_str_mv	10.1016/j.adro.2021.100854
author2-role	verfasserin
title_sort	dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging for response evaluation after single-dose ablative neoadjuvant partial breast irradiation
callnumber	R895-920
title_auth	Dynamic Contrast-enhanced and Diffusion-weighted Magnetic Resonance Imaging for Response Evaluation After Single-Dose Ablative Neoadjuvant Partial Breast Irradiation
abstract	Purpose: We aimed to evaluate changes in dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) scans acquired before and after single-dose ablative neoadjuvant partial breast irradiation (NA-PBI), and explore the relation between semiquantitative MRI parameters and radiologic and pathologic responses. Methods and Materials: We analyzed 3.0T DCE and DW-MRI of 36 patients with low-risk breast cancer who were treated with single-dose NA-PBI, followed by breast-conserving surgery 6 or 8 months later. MRI was acquired before NA-PBI and 1 week, 2, 4, and 6 months after NA-PBI. Breast radiologists assessed the radiologic response and breast pathologists scored the pathologic response after surgery. Patients were grouped as either pathologic responders or nonresponders (<10% vs ≥10% residual tumor cells). The semiquantitative MRI parameters evaluated were time to enhancement (TTE), 1-minute relative enhancement (RE1min), percentage of enhancing voxels (%EV), distribution of washout curve types, and apparent diffusion coefficient (ADC). Results: In general, the enhancement increased 1 week after NA-PBI (baseline vs 1 week median – TTE: 15s vs 10s; RE1min: 161% vs 197%; %EV: 47% vs 67%) and decreased from 2 months onward (6 months median – TTE: 25s; RE1min: 86%; %EV: 12%). Median ADC increased from 0.83 × 10−3 mm2/s at baseline to 1.28 × 10−3 mm2/s at 6 months. TTE, RE1min, and %EV showed the most potential to differentiate between radiologic responses, and TTE, RE1min, and ADC between pathologic responses. Conclusions: Semiquantitative analyses of DCE and DW-MRI showed changes in relative enhancement and ADC 1 week after NA-PBI, indicating acute inflammation, followed by changes indicating tumor regression from 2 to 6 months after radiation therapy. A relation between the MRI parameters and radiologic and pathologic responses could not be proven in this exploratory study.
abstractGer	Purpose: We aimed to evaluate changes in dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) scans acquired before and after single-dose ablative neoadjuvant partial breast irradiation (NA-PBI), and explore the relation between semiquantitative MRI parameters and radiologic and pathologic responses. Methods and Materials: We analyzed 3.0T DCE and DW-MRI of 36 patients with low-risk breast cancer who were treated with single-dose NA-PBI, followed by breast-conserving surgery 6 or 8 months later. MRI was acquired before NA-PBI and 1 week, 2, 4, and 6 months after NA-PBI. Breast radiologists assessed the radiologic response and breast pathologists scored the pathologic response after surgery. Patients were grouped as either pathologic responders or nonresponders (<10% vs ≥10% residual tumor cells). The semiquantitative MRI parameters evaluated were time to enhancement (TTE), 1-minute relative enhancement (RE1min), percentage of enhancing voxels (%EV), distribution of washout curve types, and apparent diffusion coefficient (ADC). Results: In general, the enhancement increased 1 week after NA-PBI (baseline vs 1 week median – TTE: 15s vs 10s; RE1min: 161% vs 197%; %EV: 47% vs 67%) and decreased from 2 months onward (6 months median – TTE: 25s; RE1min: 86%; %EV: 12%). Median ADC increased from 0.83 × 10−3 mm2/s at baseline to 1.28 × 10−3 mm2/s at 6 months. TTE, RE1min, and %EV showed the most potential to differentiate between radiologic responses, and TTE, RE1min, and ADC between pathologic responses. Conclusions: Semiquantitative analyses of DCE and DW-MRI showed changes in relative enhancement and ADC 1 week after NA-PBI, indicating acute inflammation, followed by changes indicating tumor regression from 2 to 6 months after radiation therapy. A relation between the MRI parameters and radiologic and pathologic responses could not be proven in this exploratory study.
abstract_unstemmed	Purpose: We aimed to evaluate changes in dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) scans acquired before and after single-dose ablative neoadjuvant partial breast irradiation (NA-PBI), and explore the relation between semiquantitative MRI parameters and radiologic and pathologic responses. Methods and Materials: We analyzed 3.0T DCE and DW-MRI of 36 patients with low-risk breast cancer who were treated with single-dose NA-PBI, followed by breast-conserving surgery 6 or 8 months later. MRI was acquired before NA-PBI and 1 week, 2, 4, and 6 months after NA-PBI. Breast radiologists assessed the radiologic response and breast pathologists scored the pathologic response after surgery. Patients were grouped as either pathologic responders or nonresponders (<10% vs ≥10% residual tumor cells). The semiquantitative MRI parameters evaluated were time to enhancement (TTE), 1-minute relative enhancement (RE1min), percentage of enhancing voxels (%EV), distribution of washout curve types, and apparent diffusion coefficient (ADC). Results: In general, the enhancement increased 1 week after NA-PBI (baseline vs 1 week median – TTE: 15s vs 10s; RE1min: 161% vs 197%; %EV: 47% vs 67%) and decreased from 2 months onward (6 months median – TTE: 25s; RE1min: 86%; %EV: 12%). Median ADC increased from 0.83 × 10−3 mm2/s at baseline to 1.28 × 10−3 mm2/s at 6 months. TTE, RE1min, and %EV showed the most potential to differentiate between radiologic responses, and TTE, RE1min, and ADC between pathologic responses. Conclusions: Semiquantitative analyses of DCE and DW-MRI showed changes in relative enhancement and ADC 1 week after NA-PBI, indicating acute inflammation, followed by changes indicating tumor regression from 2 to 6 months after radiation therapy. A relation between the MRI parameters and radiologic and pathologic responses could not be proven in this exploratory study.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	2
title_short	Dynamic Contrast-enhanced and Diffusion-weighted Magnetic Resonance Imaging for Response Evaluation After Single-Dose Ablative Neoadjuvant Partial Breast Irradiation
url	https://doi.org/10.1016/j.adro.2021.100854 https://doaj.org/article/751cb4f60910424aab7700d239593d68 http://www.sciencedirect.com/science/article/pii/S2452109421002128 https://doaj.org/toc/2452-1094
remote_bool	true
author2	Maureen L. Groot Koerkamp, MSc Stefano Mandija, PhD Wouter B. Veldhuis, PhD Maaike R. Moman, PhD Martijn Froeling, PhD Bas H.M. van der Velden, PhD Ramona K. Charaghvandi, PhD Celien P.H. Vreuls, PhD Paul J. van Diest, PhD A.M. Gijs van Leeuwen, MD Joost van Gorp, PhD Marielle E.P. Philippens, PhD Bram van Asselen, PhD Jan J.W. Lagendijk, PhD Helena M. Verkooijen, PhD H.J.G. Desirée van den Bongard, PhD Antonetta C. Houweling, PhD
author2Str	Maureen L. Groot Koerkamp, MSc Stefano Mandija, PhD Wouter B. Veldhuis, PhD Maaike R. Moman, PhD Martijn Froeling, PhD Bas H.M. van der Velden, PhD Ramona K. Charaghvandi, PhD Celien P.H. Vreuls, PhD Paul J. van Diest, PhD A.M. Gijs van Leeuwen, MD Joost van Gorp, PhD Marielle E.P. Philippens, PhD Bram van Asselen, PhD Jan J.W. Lagendijk, PhD Helena M. Verkooijen, PhD H.J.G. Desirée van den Bongard, PhD Antonetta C. Houweling, PhD
ppnlink	848324579
callnumber-subject	R - General Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1016/j.adro.2021.100854
callnumber-a	R895-920
up_date	2024-07-03T14:20:37.223Z
_version_	1803567955679641600
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ075338785</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309133523.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.adro.2021.100854</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ075338785</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ751cb4f60910424aab7700d239593d68</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R895-920</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Jeanine E. Vasmel, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Dynamic Contrast-enhanced and Diffusion-weighted Magnetic Resonance Imaging for Response Evaluation After Single-Dose Ablative Neoadjuvant Partial Breast Irradiation</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose: We aimed to evaluate changes in dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) scans acquired before and after single-dose ablative neoadjuvant partial breast irradiation (NA-PBI), and explore the relation between semiquantitative MRI parameters and radiologic and pathologic responses. Methods and Materials: We analyzed 3.0T DCE and DW-MRI of 36 patients with low-risk breast cancer who were treated with single-dose NA-PBI, followed by breast-conserving surgery 6 or 8 months later. MRI was acquired before NA-PBI and 1 week, 2, 4, and 6 months after NA-PBI. Breast radiologists assessed the radiologic response and breast pathologists scored the pathologic response after surgery. Patients were grouped as either pathologic responders or nonresponders (<10% vs ≥10% residual tumor cells). The semiquantitative MRI parameters evaluated were time to enhancement (TTE), 1-minute relative enhancement (RE1min), percentage of enhancing voxels (%EV), distribution of washout curve types, and apparent diffusion coefficient (ADC). Results: In general, the enhancement increased 1 week after NA-PBI (baseline vs 1 week median – TTE: 15s vs 10s; RE1min: 161% vs 197%; %EV: 47% vs 67%) and decreased from 2 months onward (6 months median – TTE: 25s; RE1min: 86%; %EV: 12%). Median ADC increased from 0.83 × 10−3 mm2/s at baseline to 1.28 × 10−3 mm2/s at 6 months. TTE, RE1min, and %EV showed the most potential to differentiate between radiologic responses, and TTE, RE1min, and ADC between pathologic responses. Conclusions: Semiquantitative analyses of DCE and DW-MRI showed changes in relative enhancement and ADC 1 week after NA-PBI, indicating acute inflammation, followed by changes indicating tumor regression from 2 to 6 months after radiation therapy. A relation between the MRI parameters and radiologic and pathologic responses could not be proven in this exploratory study.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical physics. Medical radiology. Nuclear medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maureen L. Groot Koerkamp, MSc</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stefano Mandija, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Wouter B. Veldhuis, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maaike R. Moman, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Martijn Froeling, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bas H.M. van der Velden, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ramona K. Charaghvandi, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Celien P.H. Vreuls, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paul J. van Diest, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A.M. Gijs van Leeuwen, MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Joost van Gorp, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marielle E.P. Philippens, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bram van Asselen, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jan J.W. Lagendijk, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Helena M. Verkooijen, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">H.J.G. Desirée van den Bongard, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonetta C. Houweling, PhD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Advances in Radiation Oncology</subfield><subfield code="d">Elsevier, 2016</subfield><subfield code="g">7(2022), 2, Seite 100854-</subfield><subfield code="w">(DE-627)848324579</subfield><subfield code="w">(DE-600)2847724-8</subfield><subfield code="x">24521094</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:100854-</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.adro.2021.100854</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/751cb4f60910424aab7700d239593d68</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S2452109421002128</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2452-1094</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2022</subfield><subfield code="e">2</subfield><subfield code="h">100854-</subfield></datafield></record></collection>
score	7.399295

Nicht das Richtige dabei?

Schreiben Sie uns!

Dynamic Contrast-enhanced and Diffusion-weighted Magnetic Resonance Imaging for Response Evaluation After Single-Dose Ablative Neoadjuvant Partial Breast Irradiation

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?